Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06661720CT.gov Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Pelvis Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tivozanib (this asset) | Alliance for Clinical Trials in Oncology | P3 | B · 56 |
| Cis-Diamminedichloroplatinum Ii | H. Lee Moffitt Cancer Center and Research Institute | P3 | BB |
| Vinflunine | Dr Anders Ullén | P2 | BB |
| Pembrolizumab | Alliance for Clinical Trials in Oncology | P3 | B |
| Docetaxel | Eli Lilly and Company | P2 | B |
| Icrucumab | Eli Lilly and Company | P2 | B |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer | Eli Lilly and Company | P2 | B |
| Carboplatin | Dr Anders Ullén | P2 | B |
| Nivolumab | M.D. Anderson Cancer Center | P2 | CCC |
+9 more in the Renal Pelvis Carcinoma cohort
Other indications for Tivozanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | B · 62 |
| Hepatocellular Carcinoma | — | P2 | B · 58 |
| Nonpapillary Renal Cell Carcinoma | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tivozanib in Renal Pelvis Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tivozanib-renal-pelvis-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →